• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Piramal Pharma Ltd.
    14 May 2024
    198.94
    -0.85%
    In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal
    In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal
    Economic Times
    Nandini Piramal projects early teens revenue growth for FY25 and 22-25% EBITDA growth margins in 3-5 years. Revenue increase drives margin expansion through cost optimization and operational excellence, with a focus on CDMO and Indian consumer products growth.
    Copy LinkShare onShare on Share on Share on
    Piramal Pharma Ltd. is trading above its 50 day SMA of 198.6
    logo
    Piramal Pharma Ltd.
    13 May 2024
    198.94
    -0.85%
    On-patent and differentiated offerings will give Piramal Pharma an edge, says Chairperson
    Business Line
    The strategy is to stay the course and grow CDM and consumer healthcare businesses
    Copy LinkShare onShare on Share on Share on
    Piramal Pharma Ltd. has an average target of 267.00 from 4 brokers.
    Piramal Pharma Shares At 52-Week High After Profit Doubles
    NDTV Profit | 13 May 2024
    logo
    Cipla Ltd.
    13 May 2024
    1541.20
    -0.79%
    Broker's call: Cipla (Buy)
    Business Line
    Choice Equity
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.
    Cipla shares surge over 6% post Q4 results. Should you buy or sell?
    Economic Times | 13 May 2024 2 more
    Cipla Shares Surge As Q4 Profit Beats Estimates
    NDTV Profit | 13 May 2024
    Cipla Q4 Results Review - Strong All-Round Performance: Nirmal Bang
    NDTV Profit | 13 May 2024
    logo
    Neuland Laboratories Ltd.
    13 May 2024
    14449.00
    -0.07%
    Neuland Labs Shares Tumble Nearly 15% After Profit Declines 20% In Q4
    Neuland Labs Shares Tumble Nearly 15% After Profit Declines 20% In Q4
    NDTV Profit
    The company reported a consolidate net profit of Rs 67.6 crore during the January-March quarter, compared with Rs 84.5 crore a year ago, beating Bloomberg estimated of Rs 24.4 crore.
    Copy LinkShare onShare on Share on Share on
    Neuland Laboratories Ltd. is trading above all available SMAs
    logo
    Piramal Pharma Ltd.
    10 May 2024
    198.94
    -0.85%
    Piramal Pharma Q4 Results: Profit Rises, But Misses Estimates
    Piramal Pharma Q4 Results: Profit Rises, But Misses Estimates
    NDTV Profit
    Net profit of the company rose two times YoY to Rs 101.27 crore in the fourth quarter, as compared with Rs 50.11 crore in the year-ago period.
    Copy LinkShare onShare on Share on Share on
    Piramal Pharma Ltd. is trading below its 100 day SMA of 203.1
    logo
    Cipla Ltd.
    10 May 2024
    1541.20
    -0.79%
    Cipla keen on obesity segment, to bring out products on its own or though partnership
    Business Line
    Profit after tax was up 79 per cent in Q4 at at 939 crore
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1702.60 from 10 brokers.
    Cipla Declares Highest-Ever Dividend Of Rs 13 Per Share
    NDTV Profit | 10 May 2024 1 more
    Cipla Q4 Results: Profit Rises 79%; Beats Estimates
    NDTV Profit | 10 May 2024
    logo
    Strides Pharma Science Ltd.
    10 May 2024
    881.40
    -1.01%
    Strides Pharma Science's shares rise 1.64% on USFDA approval
    Business Line
    Strides Pharma Science's subsidiary Strides Pharma Global Pte Limited received USFDA's approval for Sevelamer Carbonate Tablets
    Copy LinkShare onShare on Share on Share on
    Promoters unpledged 1.88% of shares in last quarter. Total pledge stands at 50.10% of promoter holdings
    logo
    Abbott India Ltd.
    10 May 2024
    30965.00
    -0.59%
    Abbott India Q4 Results Review - Highest-Ever Ebitda Margins: Axis Securities
    Abbott India Q4 Results Review - Highest-Ever Ebitda Margins: Axis Securities
    NDTV Profit
    The company's gross margins improved by 57 bps YoY due to changes in product mix and a fall in raw material prices.
    Copy LinkShare onShare on Share on Share on
    Abbott India Ltd. is trading below its 30 day SMA of 32745.2
    Abbott India Announces Final Dividend Of Rs 410 Per Share
    NDTV Profit | 09 May 2024
    logo
    Alembic Pharmaceuticals Ltd.
    10 May 2024
    947.30
    0.08%
    Alembic Pharma Q4 Results Review - New Launches In U.S., Capacity Utilisation To Drive Growth: Nirmal Bang
    Alembic Pharma Q4 Results Review - New Launches In U.S., Capacity Utilisation To Drive Growth: Nirmal Bang
    NDTV Profit
    Domestic business grew by ~3% YoY to Rs 5.03 billion.
    Copy LinkShare onShare on Share on Share on
    Alembic Pharmaceuticals Ltd. is trading below all available SMAs
    Alembic Pharmaceuticals Q4 Results: Profit Rises 17%, Beats Estimates
    NDTV Profit | 09 May 2024
    logo
    Lupin Ltd.
    09 May 2024
    US FDA Observation
    1947.20
    0.17%
    Lupin appoints former-executives from two major American companies, as independent directors to its board
    Business Line
    Former top executives from Pfizer and Eli Lilly appointed; US accounts for 37 percent of Lupin's annual sales
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd